ABSTRACT
INTRODUCTION
Chromaffin-cell tumors are tumors that can synthesize, store, and secrete catecholamines. Chromaffin-cell tumors can arise from the adrenal medulla, where they are referred to as pheochromocytomas, or from extraadrenal chromaffin tissue, referred to as paragangliomas. The incidence of chromaffin-cell tumors identified during pregnancy is extremely rare, with an incidence of 0.32 cases per 100,000 pregnancy years compared with 0.57 cases per 100,000 person-years in the general population. [1] [2] [3] Differentiating these tumors from more common causes of hypertension during pregnancy such as pre-eclampsia is of critical importance due to increased maternal morbidity and mortality as well as fetal demise when diagnosis is made late in pregnancy or postpartum. 4 Management of chromaffin-cell tumors during pregnancy is complicated by the normal physiologic changes during pregnancy such as increased intraabdominal pressure, fetal movement, uterine contractions as well as labor and delivery. 5 Herein, we describe three cases of chromaffin-cell tumors diagnosed during pregnancy at our institution. We also conducted an updated review of the literature.
U/L) and aspartate aminotransferase of 77 U/L (15 to 37 U/L). Platelet count and creatinine were normal and there was no proteinuria or lower extremity edema. An abdominal ultrasound performed denoted an incidental right-sided adrenal mass. Further evaluation with MRI revealed a 7.3 x 6.2 x 3.9 cm right adrenal mass with internal cystic degeneration and displacement of the IVC (Fig. 1) . She was transferred to a tertiary care center for further management.
Expanded clinical history revealed a several years history of hypertension as well as hypertension during prior pregnancies. She reported intermittent spells of diaphoresis, palpitations, headaches, dyspnea, and anxiety. Her first pregnancy was complicated by placental abruption at 28 weeks gestation requiring emergent cesarean section. Her postoperative course during that first pregnancy was complicated by severe hypertension up to 230/136 mm Hg and pulmonary edema requiring mechanical ventilation. She was eventually discharged in stable condition. Her second pregnancy was similarly complicated by preterm labor and a diagnosis of preeclampsia.
Upon transfer to our institution, she had severe range blood pressures as high as 202/114 mm Hg with heart rate values up to 160 bpm. Biochemical evaluation included elevated serum epinephrine 82 pg/mL (<50 pg/mL), norepinephrine 15,048 pg/mL (112 to 658 pg/mL), dopamine 297 pg/mL (<30 pg/mL), metanephrine 101 pg/mL (<57 pg/mL), and normetanephrine 4,511 pg/mL (< 148 pg/mL). Twenty-four hour urine studies demonstrated metanephrines 233 mcg/24 hour (25 to 222 mcg/24h), normetanephrine 9,393 mcg/24 hour (40 to 412 mcg/24h), and protein 186 mg/24 hour (<300 mg/24h).
Therapy for a catecholamine-secreting tumor was initiated with a phentolamine infusion at 8 mg/hr co-administered with phenoxybenzamine 10 mg TID. Phentolamine was then stopped and blood pressures normalized on phenoxybenzamine 10 mg PO BID and labetalol 100 mg PO BID with orthostatic hypotension not less than 90/50 mm Hg allowed. At 33 weeks premature rupture of membranes occurred and cesarean delivery was performed. Intraoperatively the apex arterial blood pressure recorded was 175/115 mm Hg with postoperative blood pressure 144/86 mm Hg. At birth, the infant weighed 2090 grams, had APGAR scores of 1/3/5/6, and was in NICU 3 weeks. No other maternal or fetal complications occurred.
Three months postpartum, the patient underwent open right adrenalectomy. Intraoperative arterial blood pressure peaked at 208/120 mm Hg. The surgical pathologic evaluation demonstrated a pheochromocytoma with focal invasion into but not through the capsule, no vascular invasion, and <4 mitotic figures/10 high power fields. Surgical margins were free of tumor. The patient was discharged home post-operative day 5 in stable condition.
Case 2
A 23-year-old G1P0 at 37 weeks gestation presented with a known medical history of metastatic paraganglioma with heterozygous SDHB mutation, p.C253Y. She was diagnosed at age 10 and underwent surgical resection of a left adrenal mass, which demonstrated positive chromogranin and synaptophysin on histology. At age 21 during an appendectomy, a retroperitoneal mass and multiple metastatic lesions were identified, as were a 2.3 cm left adrenal mass, a 6 cm aortocaval mass, and several bony lesions involving right iliac bone, left ischial ramus, multiple thoracic and lumbar vertebrae (Fig. 2) . She underwent autologous stem cell apheresis and 530 mCi I-131 MIGB therapy.
She was admitted for observation at an outside hospital at 37 weeks gestation for intermittent hypertension at home. She reported home blood pressures of 215/125 mm Hg with headaches. During observation, her maximum blood pressure was 230/107 mm Hg. Biochemical evaluation revealed: 24-hour urine normetanephrine elevated at 4789 mcg/24 hour (40 to 412 mcg/24h), metanephrine 63 mcg/24 hour (25 to 222 mcg/24h), total protein 223.50 mg/24 hour (< 300 mg/24h). Intravenous phentolamine 5 mg Q 4 hours was initiated. Once blood pressure control was achieved, she was transitioned from phentolamine to phenoxybenzamine 10 mg PO BID and labetalol 100 mg PO BID. 
WJOES
She underwent a scheduled cesarean section at 38 weeks gestation of a 3,650g infant with APGARs 6/7/8. Her highest recorded intraoperative arterial blood pressure was 165/100 mm Hg. Her postoperative course was complicated by a seizure without hemodynamic changes that was ultimately attributed to calvarial metastases stretching the dura. Both the patient and infant were eventually discharged in stable condition.
Case 3
A 28-year-old female G3P1011 was diagnosed with a left pheochromocytoma at 32 weeks gestation. Her past medical history included a diagnosis of MEN2A, status post right total adrenalectomy for a pheochromocytoma, medullary thyroid carcinoma status post total thyroidectomy and primary hyperparathyroidism status post subtotal parathyroidectomy.
On biochemical evaluation at 25 weeks gestation, serum normetanephrine was 1.6 nmol/L (<0.90 nmol/L), metanephrine 0.75 nmol/L (<0.50 nmol/L), 24 hour urine metanephrine 718 mcg/24 hour (30 to 180 mcg/24h), and normetanephrine 833 mcg/24 hour (103 to 390 mcg/24h).
Abdominal MRI was performed and demonstrated a T2 hyperintense 1.9 cm left adrenal lesion, with no signal loss on out of phase imaging suggestive of a pheochromocytoma (Fig. 3) .
She was treated with 1 mg daily doxazosin. She underwent scheduled cesarean delivery at 39 weeks during which maximum arterial blood pressure was 165/95 mm Hg. No maternal or fetal complications occurred. At birth, the infant was 3,380 grams with APGARs 9/9.
Four months postpartum, she underwent an uneventful robotic left partial adrenalectomy. Maximum arterial blood pressure intraoperatively was 195/105 mm Hg. She recovered without complication.
Methods
An updated review of full-text English language cases published since 2014 was performed systematically. Search engines included MEDLINE, EMBASE and Google Scholar with the terms (pheochromocytoma or paraganglioma) and (pregnancy or pregnant) within the timeframe 2014 through 2018 (searched on April 9th, 2018). After excluding duplicate articles and abstract only articles, published data were aggregated. Cases were included if the diagnosis of a chromaffin-cell tumor was clearly described, as well as the timing of diagnosis, presenting symptoms, the location of the tumor, delivery method, medical or surgical complications, maternal and neonatal outcomes. Cases were excluded if they were written in a language other than English or missing two or more of the inclusion criteria. Composite outcome data were analyzed and reported. Two subgroups were identified; patients with chromaffin-cell tumor diagnosed during the antenatal period and patients with a chromaffin-cell tumor diagnosed postpartum, after acute illness leading to an emergency cesarean section, or maternal or fetal death. A two-tailed Fisher's exact test was performed on the two identified subgroups comparing maternal survival, fetal survival, emergency cesarean section and preterm labor. Our hypothesis was that there would be more complications for late or missed diagnosis of the chromaffin-cell tumor during pregnancy.
There were 63 cases identified after exclusion of 40 duplicate records, 35 abstract only records, 9 non-English publications and 80 articles without a clinical case reported (Fig. 4) . A total of 40 manuscripts were included reporting on 59 pregnant women. Data are summarized in Table 1 with outcome data summarized in Table 2 [Complete detailed review of cases is available as a supplementary file S1 (online only)].
RESULTS
The mean age of the women included was 29 years. The most frequently reported presenting symptoms were hypertension, tachycardia or palpitations, abdominal pain/nausea or vomiting, and headache. Forty tumors were diagnosed in the antenatal period, most commonly in the second trimester. Twenty-three tumors were diagnosed postpartum, or due to acute illness leading to an emergency cesarean section, or maternal, fetal or neonatal death. Each diagnosis of a chromaffin-cell tumor was based on the biochemical investigation, imaging and/ or histologic confirmation, in the single reported case of maternal death, an autopsy confirmed the diagnosis. Biochemical investigation performed during pregnancy demonstrated elevated catecholamines in 92% (45/49) cases. Imaging modalities utilized during pregnancy included ultrasound, magnetic resonance imaging, and computed tomography.
The most common diagnosis was unilateral pheochromocytoma 63.5% (40/63), with the remaining cases being paragangliomas 25.4% (16/63) followed by bilateral pheochromocytomas 9.5% (6/63). Genetic mutations were confirmed in 23.8% (15/63), an additional five patients had a family history SDH-B, VHL or RET mutations. The most common genetic mutations were RET proto-oncogene mutation and SDH-B mutation.
Medical treatment consisted of alpha and beta blockade. Phenoxybenzamine was the most frequently cited Severe hypertension SBP > 180 or DBP > 100 6
WJOES
Labile BP 3
Placental abruption 2
Heart failure and/or pulmonary edema 2 Hypoglycemia 1
Maternal death 0
Medical complications (diagnosis postpartum, after acute illness leading to emergency cesarean, maternal or fetal death) N = 23
Cauda equina syndrome 2
Hypertensive crisis 10
Cardiogenic shock/cardiomyopathy/heart failure with pulmonary edema 7
Heart failure without pulmonary edema 1
Pulmonary edema without heart failure 2
Heart failure and/or pulmonary edema 10 
tum (3 open procedures vs. 4 laparoscopic procedures occurred within 1 month postpartum).
Overall maternal mortality was not statistically different in women with diagnosis during or before pregnancy 0%, compared to women with a late or postpartum diagnosis 1.6% (1/23) (p = 0.37). Premature labor was also not statistically different in women with diagnosis during or before pregnancy 27.5% (11/40), compared to 43.5% (10/23) in women with a late or postpartum diagnosis (OR 2.03, 95% CI: 0.69-5.96; p = 0.27).
Emergency cesarean section delivery was more common in women with a late or postpartum diagnosis 47.8% (11/23) compared to women with diagnosis during or before pregnancy 10% (4/40), (OR 8.3, 95% CI: 2.21 to 30.81; p<0.05). Fetal or neonatal death was more common in women with a late or postpartum diagnosis 21.7%(5/23)compared to women with diagnosis during or before pregnancy 2.5% (1/40) (OR 10.8, 95% CI: 1.18 to 99.59; p <0.05). Heart failure and/or pulmonary edema was more common among women with a late or postpartum diagnosis 43.5% (10/23) compared to women with diagnosis during or before pregnancy 5% (2/40), (OR 14.6, 95% CI: 2.82 to 75.62; p < 0.001) ( Table 3 ).
DISCUSSION
We have described three cases of chromaffin-cell tumors detailing their presentations and management strategies. All three patients received an alpha-blocker during their third trimester, two women additionally received a beta blocker. All women underwent an uncomplicated cesarean section with two patients having delayed adrenalectomy post-partum. We additionally performed a systematic review of the most recently published case reports since 2014. We identified an increased rate of the emergency cesarean section, maternal heart failure or pulmonary edema, and fetal or neonatal death among women with a late diagnosis of a chromaffin-cell tumor in pregnancy. Our results demonstrate the importance of early diagnosis of these rare but clinically important tumors.
The results of our literature review demonstrated a maternal survival of 98% regardless of the timing of diagnosis compared with maternal mortality as high as 28.6% in a prior literature review for women with a late diagnosis. 5 A systematic review of cases performed from 1998 to 2013 identified 143 cases of chromaffin-cell cell tumors during pregnancy. Analysis of these cases demonstrated an overall maternal mortality rate of 7.3% and fetal mortality of 15.9%. Maternal mortality was 9.8% in patients with pheochromocytoma compared to the maternal mortality of 3.6% in patients with paragangliomas. The diagnosis was made during or before pregnancy in 83% of cases. 6 The difference in maternal mortality noted in our literature review is likely a result of newer technologies and improved care of the critically ill. The single maternal death in our review was a patient who presented with respiratory failure, fetal demise, and cardiac arrest as a result of ventricular fibrillation. Maternal complications were more severe in the group of women with diagnosis postpartum, after acute illness leading to emergency cesarean, or after maternal or fetal death. In this group, there were four cardiopulmonary arrests, multiple cases of cardiogenic shock, cardiomyopathy, pulmonary edema, and multiorgan failure. The group of patients with the antenatal diagnosis had one episode of heart failure with pulmonary edema.
Medical management in pregnancy is similar to that of non-pregnant patients and includes alpha-adrenergic blockade. Phenoxybenzamine use is the most frequently cited alpha blocker used in case reports. Phenoxybenzamine use is traditionally thought of as the best intraoperative catecholamine blocker as it is a noncompetitive antagonist. A recent multi-institutional randomized controlled trial demonstrated the equal efficacy of doxazosin and phenoxybenzamine in controlling perioperative hemodynamics during surgical resection of pheochromocytoma. 7 Beta blockade or calcium channel blockers should be considered for reflexive tachycardia after initiation of the alpha blockade. Both phenoxybenzamine and doxazosin cross the placenta and rarely, have resulted in neonatal hypotension and respiratory depression related to their long half-life in the fetal circulation before delivery. Fetal-to-maternal plasma ratio of phenoxybenzamine has been shown to be higher than doxazosin 1.6 vs. 0.8, respectively. A low percentage of doxazosin and phenoxybenzamine are excreted into breast milk, around 1% of the maternal dose. 8 All alpha blockers are pregnancy category C. Target blood pressure management have not formally been established. Goal blood pressure targets must be balanced between maternal catecholamine blockage and maintaining adequate uteroplacental perfusion. 5 Surgical and delivery management is dependent on the stability of the mother with alpha-blockade leading up to the delivery date. In general, if a chromaffin-cell tumor is diagnosed before the 3rd trimester and appears benign on imaging, laparoscopic adrenalectomy during pregnancy should be considered. If the diagnosis occurs during the 3rd trimester, the patient should be managed medically until delivery vaginally or via cesarean section with concurrent or delayed adrenalectomy. Vaginal delivery was previously discouraged because of concerns that uterine contractions and labor would release catecholamines. However, given the lack of definitive outcome data either delivery modality may be utilized. [9] [10] [11] If peripartum adrenalectomy is planned, a multidisciplinary team should be established to coordinate delivery timing. Reasons to delay adrenalectomy postpartum include; reduced vascularity, opportunity to obtain contrast-enhanced cross-sectional imaging, as well as improved visual access to abdominal viscera. The surgical and anesthesia teams should be skilled in the anesthetic and surgical management of catecholamine-producing tumors and should be on standby before and during delivery. After delivery, the patient should be monitored closely for cardiac instability. 5 There is no formal recommendation for or against preoperative echocardiogram. However, maternal echocardiogram should be considered in patients with large pheochromocytomas or patients with late or postpartum diagnoses.
CONCLUSION
All providers who manage patients during pregnancy should consider chromaffin-cell tumors as a possible etiology for cases of gestational hypertension or atypical preeclampsia. Hypertension is the most common presenting symptom of the catecholamine-producing tumor during pregnancy. 4 Severe hypertension, labile hypertension, or hypertension before 20 weeks, without proteinuria or lower extremity edema, should raise suspicion for a chromaffin-cell tumor. After securing the diagnosis of a catecholamine-producing tumor during pregnancy, establishing a dedicated team consisting of obstetric, surgery, anesthesiology, intensive care and pediatrics at a tertiary referral hospital is critical to ensure the optimal maternal-fetal outcome. 
